France's National Assembly has now confirmed the imposition of a 2.5%"contribution" by the pharmaceutical industry, under Article 8, section 2 of th revized social security code (Marketletters passim). The contribution - or rather tax - will be levied on drugmakers' sales (excluding taxes) direct to pharmacists, with the specific exception of generic specialties.
The legislation goes on to state that when a drug company has not produced a sales declaration with the requisite detail in the time allotted, or has produced a "manifestly incorrect" declaration, the provisional rate of the contribution will be 10% - calculated on the last-known direct sales figure or by other means if this is necessary.
The 10% rate will also apply if a company is late in making declarations. Moreover, the levy will have to be paid by drugmakers on the last day of each quarter at the latest, on the basis of the sales achieved in the preceding quarter.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze